Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Controlled Clinical Trial
. 2022 May 11;20(1):154.
doi: 10.1186/s12957-022-02621-2.

Effect of bevacizumab combined with chemotherapy on SDF-1 and CXCR4 in epithelial ovarian cancer and its prognosis

Chunyan Ma  1
Affiliations
Controlled Clinical Trial

Effect of bevacizumab combined with chemotherapy on SDF-1 and CXCR4 in epithelial ovarian cancer and its prognosis

Chunyan Ma. World J Surg Oncol. .

Abstract

Background: The effect of bevacizumab combined with chemotherapy on the expression of stromal cell-derived factor-1 (SDF-1) and receptor CXCR4 in epithelial ovarian cancer tumor cells and its prognosis are unknown. Our work aimed to investigate the effect of chemotherapy +/- bevacizumab on these markers and the impact of this treatment modality in clinical outcomes.

Methods: Altogether 68 patients with epithelial ovarian cancer who were treated with chemotherapy in our hospital from June 2018 to June 2019 were selected. It was an open-labeled and controlled clinical trial (ethical approval no. 20180435). The patients were grouped according to their admission order. Patients treated with paclitaxel and carboplatin were included in group A, while patients treated with bevacizumab, paclitaxel, and carboplatin were included in group B. qRT-PCR was used to detect the changes of SDF-1 and CXCR4 before and after chemotherapy. Various clinical indicators of patients in the two groups were recorded to analyze the clinical efficacy, and safety of different treatment modalities and the prognosis of the two groups was analyzed.

Results: The relative expression of SDF-1 and CXCR4 was positively correlated with epithelial ovarian cancer stages (P<0.00). Together, SDF-1 and CXCR4 were positively correlated in epithelial ovarian cancer staging (P<0.001). SDF-1 and CXCR4 in both groups after chemotherapy were significantly decreased (P<0.001), and the downregulation of SDF-1 and CXCR4 expression in group B was significantly higher than that in group A after chemotherapy (P<0.001). No significant difference in the metastasis rates of the two groups before chemotherapy was observed (P>0.05), but the recurrence rate after 1 year was lower in group B than in group A (P<0.05).

Conclusion: Adding bevacizumab diminished the expression of related cancer markers SDF-1 and CXCR4 more than chemotherapy alone in patients with epithelial ovarian cancer. Furthermore, better rates of recurrence with no concerns regarding adverse drug reactions or quality of life were seen in bevacizumab plus chemotherapy group.

Keywords: Bevacizumab; CXCR4; Chemotherapy; Epithelial ovarian cancer; SDF-1.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Comparison of median survival of patients in the two groups. The horizontal axis indicated the month, and the vertical axis indicated the survival rate (%); the gray curve indicated the survival curve of group A, and the black curve indicated the survival curve of group B
Fig. 2
Fig. 2
Comparison of quality of life between group A and group B after intervention. The scores of physical health (A), mental health (B), material life (C), and social function (D) in group B were significantly higher than those in group A (P<0.001)
Fig. 3
Fig. 3
Expression of SDF-1 in group A and group B. A Expression level of SDF-1 in group A and group B (P>0.05); B Expression of CXCR4 increased with the illness of group A patients in stages II, III, and IV, and the relative expression of SDF-1 increased. C Spearman correlation analysis showed that the relative expression of SDF-1 was positively correlated with the stage of epithelial ovarian cancer (P<0.001)
Fig. 4
Fig. 4
Expression of CXCR4 in group A and group B. A Expression level of CXCR4 in group A and group B (P>0.05); B Expression of CXCR4 increased with the illness of patients in group A in stages II, III, and IV, and the relative expression of CXCR4 increased accordingly; C Spearman correlation analysis showed that the relative expression of CXCR4 was positively correlated with epithelial ovarian cancer staging (P<0.001). D SDF-1 and CXCR4 were positively correlated in epithelial ovarian cancer staging (P<0.001)
Fig. 5
Fig. 5
Changes of SDF-1 and CXCR4 in group A and group B after chemotherapy. A After chemotherapy, the decrease of SDF-1 in group B was significantly higher than that in group A, a indicates P<0.001. B After chemotherapy, the decrease of CXCR4 in group B was significantly higher than that in group A, a indicates P<0.001
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14:9–32. doi: 10.20892/j.issn.2095-3941.2016.0084. - DOI - PMC - PubMed
    1. Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68:284–296. doi: 10.3322/caac.21456. - DOI - PMC - PubMed
    1. Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387:945–956. doi: 10.1016/S0140-6736(15)01224-6. - DOI - PMC - PubMed
    1. Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154–2164. doi: 10.1056/NEJMoa1611310. - DOI - PubMed
    1. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384:1376–1388. doi: 10.1016/S0140-6736(13)62146-7. - DOI - PubMed

Publication types